Advertisement

FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope?

  • Clara Helal
    Correspondence
    Corresponding author: Gustave Roussy Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France. Tel.: (+33)01 42 11 42 11
    Affiliations
    Medical Oncology Department, Institut Gustave Roussy, Université Paris Saclay, Paris, France
    Search for articles by this author
  • Marine Valéry
    Affiliations
    Medical Oncology Department, Institut Gustave Roussy, Université Paris Saclay, Paris, France
    Search for articles by this author
  • Michel Ducreux
    Affiliations
    Medical Oncology Department, Institut Gustave Roussy, Université Paris Saclay, Paris, France
    Search for articles by this author
  • Antoine Hollebecque
    Affiliations
    Medical Oncology Department, Institut Gustave Roussy, Université Paris Saclay, Paris, France

    Department of Therapeutic Innovation and Early Trials, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France
    Search for articles by this author
  • Cristina Smolenschi
    Correspondence
    Corresponding author: Gustave Roussy Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France. Tel.: (+33)01 42 11 42 11
    Affiliations
    Medical Oncology Department, Institut Gustave Roussy, Université Paris Saclay, Paris, France

    Department of Therapeutic Innovation and Early Trials, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France
    Search for articles by this author
Published:October 13, 2022DOI:https://doi.org/10.1016/j.ejca.2022.09.016
      Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with dismal prognosis, projected to be the second cause of cancer-related deaths worldwide by 2030 [
      • Rahib L.
      • Smith B.D.
      • Aizenberg R.
      • Rosenzweig A.B.
      • Fleshman J.M.
      • Matrisian L.M.
      Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
      ]. Most of the patients will present already a locally advanced or metastatic disease at diagnosis and systemic chemotherapy remains their main therapeutical option [
      • Mizrahi J.D.
      • Surana R.
      • Valle J.W.
      • Shroff R.T.
      Pancreatic cancer.
      ]. In firstline, not only the Folfirinox regimen (5 fluorouracil (5FU), oxaliplatin, irinotecan and leucovorin) but also the combination of gemcitabine and nab-paclitaxel (nanoparticle albumin-bound paclitaxel) have demonstrated their superiority in survival over gemcitabine [
      • Conroy T.
      • Desseigne F.
      • Ychou M.
      • Bouché O.
      • Guimbaud R.
      • Bécouarn Y.
      • et al.
      FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
      ,
      • Von Hoff D.D.
      • Ervin T.
      • Arena F.P.
      • Chiorean E.G.
      • Infante J.
      • Moore M.
      • et al.
      Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
      ]. However, the median overall survival is less than a year, with limited therapeutic options in further lines.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rahib L.
        • Smith B.D.
        • Aizenberg R.
        • Rosenzweig A.B.
        • Fleshman J.M.
        • Matrisian L.M.
        Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
        Cancer Res. 1 juin 2014; 74: 2913-2921
        • Mizrahi J.D.
        • Surana R.
        • Valle J.W.
        • Shroff R.T.
        Pancreatic cancer.
        Lancet. 27 juin 2020; 395: 2008-2020
        • Conroy T.
        • Desseigne F.
        • Ychou M.
        • Bouché O.
        • Guimbaud R.
        • Bécouarn Y.
        • et al.
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. 12 mai 2011; 364: 1817-1825
        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • Chiorean E.G.
        • Infante J.
        • Moore M.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 31 oct 2013; 369: 1691-1703
        • Waddell N.
        • Pajic M.
        • Patch A.M.
        • Chang D.K.
        • Kassahn K.S.
        • Bailey P.
        • et al.
        Whole genomes redefine the mutational landscape of pancreatic cancer.
        Nature. févr 2015; 518: 495-501
        • Witkiewicz A.K.
        • McMillan E.A.
        • Balaji U.
        • Baek G.
        • Lin W.C.
        • Mansour J.
        • et al.
        Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
        Nat Commun. 9 avr 2015; 6: 6744
        • Pishvaian M.J.
        • Blais E.M.
        • Brody J.R.
        • Lyons E.
        • DeArbeloa P.
        • Hendifar A.
        • et al.
        Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
        Lancet Oncol. avr 2020; 21: 508-518
        • Javle M.M.
        • Roychowdhury S.
        • Kelley R.K.
        • Sadeghi S.
        • Macarulla T.
        • Waldschmidt D.T.
        • et al.
        Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
        J Clin Orthod. 20 janv 2021; 39 (265-265)
        • Helsten T.
        • Elkin S.
        • Arthur E.
        • Tomson B.N.
        • Carter J.
        • Kurzrock R.
        The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing.
        Clin Cancer Res. 1 janv 2016; 22: 259-267
        • Poon D.
        • Tan M.H.
        • Khor D.
        Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor.
        BMJ Case Reports CP. 1 sept 2021; 14: e244271
        • Smolle E.
        • Pichler M.
        Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition.
        Cancers (Basel). 10 févr 2019; 11: E204
        • Abou-Alfa G.K.
        • Bibeau K.
        • Schultz N.
        • Yaqubie A.
        • Millang B.M.
        • Ren H.
        • et al.
        Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma.
        J Clin Orthod. 20 janv 2021; 39 (303-303)
        • Hyung S.
        • Han B.
        • Jung J.
        • Kim S.T.
        • Hong J.Y.
        • Park S.H.
        • et al.
        Incidence of FGFR2 amplification and FGFR2 fusion in patients with metastatic cancer using clinical sequencing. Wu G, éditeur.
        J Oncol. 18 mars 2022; 20229714570